Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (1,248) Arrow Down
Filter Results: (1,248) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,248)
    • People  (5)
    • News  (172)
    • Research  (929)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (759)

Show Results For

  • All HBS Web  (1,248)
    • People  (5)
    • News  (172)
    • Research  (929)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (759)
← Page 46 of 1,248 Results →
  • April 1989 (Revised July 1992)
  • Supplement

Technology Transfer: Anti-Inflammatory Drug (B)

By: Regina E. Herzlinger
Keywords: Health; Pharmaceutical Industry
Citation
Find at Harvard
Related
Herzlinger, Regina E. "Technology Transfer: Anti-Inflammatory Drug (B)." Harvard Business School Supplement 189-166, April 1989. (Revised July 1992.)
  • February 2006 (Revised July 2007)
  • Case

Corporate Venture Capital at Eli Lilly

By: Richard G. Hamermesh, Ron Laufer and David Lane
Reviews the role of corporate venture capital and its history at Eli Lilly. Also presents a challenging venture investment opportunity. View Details
Keywords: Venture Capital; Investment; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Ron Laufer, and David Lane. "Corporate Venture Capital at Eli Lilly." Harvard Business School Case 806-092, February 2006. (Revised July 2007.)
  • January 2006 (Revised July 2006)
  • Case

Drug Testing in Nigeria (A)

By: Debora L. Spar
In 1996, a meningitis epidemic swept across Nigeria. Thousands of children were struck and, lacking appropriate medicine, were liable to die from the disease. Doctors at Pfizer had an antibiotic that could probably save most of these children's lives. The drug was new,... View Details
Keywords: Risk and Uncertainty; Health Pandemics; Health Testing and Trials; Developing Countries and Economies; Pharmaceutical Industry; Nigeria
Citation
Educators
Purchase
Related
Spar, Debora L., and Adam Day. "Drug Testing in Nigeria (A)." Harvard Business School Case 706-033, January 2006. (Revised July 2006.)
  • fall 2002
  • Article

Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial

By: Arthur A. Daemmrich
Keywords: Science; Health; Courts and Trials; Pharmaceutical Industry; Germany
Citation
Find at Harvard
Related
Daemmrich, Arthur A. "Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial." Chemical Heritage, no. 20 (fall 2002): 12–13, 28–33.
  • March 2001 (Revised June 2017)
  • Teaching Note

Vyaderm Pharmaceuticals: The EVA Decision

By: Robert Simons and Indra A. Reinbergs
Teaching Note for (9-101-019). View Details
Keywords: Pharmaceutical Industry; Washington (state, US)
Citation
Purchase
Related
Simons, Robert, and Indra A. Reinbergs. "Vyaderm Pharmaceuticals: The EVA Decision." Harvard Business School Teaching Note 101-043, March 2001. (Revised June 2017.)
  • October 2000
  • Supplement

Hans Fritz at Novartis Thailand (C)

By: Carin-Isabel Knoop and Michael Y. Yoshino
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry; Thailand
Citation
Purchase
Related
Knoop, Carin-Isabel, and Michael Y. Yoshino. "Hans Fritz at Novartis Thailand (C)." Harvard Business School Supplement 301-054, October 2000.
  • October 2000
  • Case

Procter & Gamble Italy: The Pringles Launch (A)

By: Roy D. Shapiro
Procter & Gamble's (P&G) Pringles potato chips have been a very successful brand. This case reviews the development and first launch in the United States, then in markets around the world. Italy is one of the last countries where Pringles will be launched. Should P&G... View Details
Keywords: Globalized Markets and Industries; Brands and Branding; Marketing Strategy; Product Launch; Emerging Markets; Product Development; Adoption; Value Creation; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Shapiro, Roy D. "Procter & Gamble Italy: The Pringles Launch (A)." Harvard Business School Case 601-070, October 2000.
  • September 1999
  • Teaching Note

Eli Lilly: The Evista Project TN

By: Steven C. Wheelwright
Teaching Note for (9-699-016). View Details
Keywords: Pharmaceutical Industry
Citation
Purchase
Related
Wheelwright, Steven C. "Eli Lilly: The Evista Project TN." Harvard Business School Teaching Note 600-027, September 1999.
  • June 1998
  • Supplement

MBA Integrative Exercise: General Management, April 1998

By: Carin-Isabel Knoop
Drummond Paris, Regional Pharma Head, Asia/Pacific Novartis AG, discusses the company situation in Indonesia: joint ventures, budget, keeping track, and the prognosis for the future. View Details
Keywords: Business or Company Management; Joint Ventures; Forecasting and Prediction; Pharmaceutical Industry; Indonesia
Citation
Purchase
Related
Knoop, Carin-Isabel. "MBA Integrative Exercise: General Management, April 1998." Harvard Business School Video Supplement 898-503, June 1998.
  • October 1992 (Revised September 1993)
  • Case

Nopane Advertising Strategy

By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details
Keywords: Competition; Intellectual Property; Advertising; Health Care and Treatment; Brands and Branding; Product Marketing; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Bell, David E. "Nopane Advertising Strategy." Harvard Business School Case 893-005, October 1992. (Revised September 1993.)
  • February 1998 (Revised October 1998)
  • Background Note

Note on New Drug Development in the United States

By: Stefan H. Thomke and Ashok Nimgade
An overview of the new drug development process in the United States, using the migraine drug Imitrex as an illustrative example. View Details
Keywords: Product Development; Research and Development; Health; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Thomke, Stefan H., and Ashok Nimgade. "Note on New Drug Development in the United States." Harvard Business School Background Note 698-028, February 1998. (Revised October 1998.)
  • February 1996 (Revised April 2004)
  • Case

Eli Lilly and Company: Innovation in Diabetes Care

By: Clayton M. Christensen
Summarizes Eli Lilly's history of innovation in its business, describing how the dimensions along which innovations have been made in the industry have changed. Lilly's innovation strategy has been to pursue ever higher performance products, while others in the... View Details
Keywords: Change; Product; Service Delivery; Product Development; Innovation and Management; Innovation Strategy; Health Care and Treatment; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Christensen, Clayton M. "Eli Lilly and Company: Innovation in Diabetes Care." Harvard Business School Case 696-077, February 1996. (Revised April 2004.)
  • August 1995
  • Teaching Note

Eli Lilly and Company: The Flexible Facility Decision (1993) TN

By: Gary P. Pisano
Teaching Note for (9-694-074). View Details
Keywords: Pharmaceutical Industry
Citation
Purchase
Related
Pisano, Gary P. "Eli Lilly and Company: The Flexible Facility Decision (1993) TN." Harvard Business School Teaching Note 696-041, August 1995.
  • February 1987 (Revised January 1989)
  • Case

SmithKline Consumer Products: The Contac Relaunch

In March 1986, a tamperer contaminated CONTAC Cold Capsules, SmithKline Consumer Product's most popular product. To relaunch CONTAC after withdrawing it from the market, the management team had to present a plan of action to the corporation board. They knew CONTAC's 25... View Details
Keywords: Safety; Crisis Management; Product Launch; Pharmaceutical Industry
Citation
Find at Harvard
Related
Kosnik, Thomas J. "SmithKline Consumer Products: The Contac Relaunch." Harvard Business School Case 588-046, February 1987. (Revised January 1989.)
  • February 1974
  • Case

Listerine Lozenges

By: Stephen A. Greyser
Keywords: Advertising Campaigns; Pharmaceutical Industry
Citation
Find at Harvard
Related
Greyser, Stephen A. "Listerine Lozenges." Harvard Business School Case 574-062, February 1974.
  • February 1992 (Revised April 1995)
  • Case

Pfizer: Global Protection of Intellectual Property

By: Lynn S. Paine and Michael Santoro
Top officials at Pfizer are assessing their strategy for improving protection of Pfizer's patents around the world. The outcome of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable intellectual property protection... View Details
Keywords: Patents; Trade; Policy; Government and Politics; Business Strategy; Agreements and Arrangements; Alliances; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; United States; Japan; Europe
Citation
Educators
Purchase
Related
Paine, Lynn S., and Michael Santoro. "Pfizer: Global Protection of Intellectual Property." Harvard Business School Case 392-073, February 1992. (Revised April 1995.)
  • August 1990 (Revised March 1991)
  • Case

Eli Lilly and Co. (C): Japan

By: Michael Y. Yoshino
Describes the process of establishing an independent operation in Japan in the mid-1980s as a result of a decision to make a major investment in the market. Describes the challenges in setting up such an operation and focuses on the role of the country manager in... View Details
Keywords: Business Divisions; Business Startups; Decisions; Investment; Growth Management; Managerial Roles; Markets; Problems and Challenges; Pharmaceutical Industry; Japan
Citation
Educators
Purchase
Related
Yoshino, Michael Y. "Eli Lilly and Co. (C): Japan." Harvard Business School Case 391-034, August 1990. (Revised March 1991.)
  • April 1989 (Revised January 1994)
  • Case

Novo Industri

By: Michael E. Porter and Michael J. Enright
Describes the structure of the insulin industry, a treatment for diabetes and Novo's strategy and competitive position in early 1982. The industry is undergoing significant change and Novo must decide how to defend and build its international position. Designed as an... View Details
Keywords: Change; Global Strategy; Industry Structures; Alliances; Competitive Strategy; Health Disorders; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Porter, Michael E., and Michael J. Enright. "Novo Industri." Harvard Business School Case 389-148, April 1989. (Revised January 1994.)
  • 07 Aug 2000
  • Research & Ideas

The Business of Biotech

coming of age of biotechnology. The disappearance of "blockbuster" drugs could create new management challenges for pharmaceutical companies. — Gary Pisano The prospect is exhilarating, but the road to this brave new biotech... View Details
Keywords: by Julia Hanna; Biotechnology; Health; Technology
  • Profile

Paul Wang

work with the MIT’s Abdul Latif Jameel Poverty Action Lab (J-PAL). “They’re a group of economists who use randomized evaluation methodologies, similar to those used in pharmaceutical trials, to assess the impact of development projects,”... View Details
  • ←
  • 46
  • 47
  • …
  • 62
  • 63
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.